{"id":5079,"date":"2019-05-21T13:03:15","date_gmt":"2019-05-21T07:33:15","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=5079"},"modified":"2021-07-24T12:57:21","modified_gmt":"2021-07-24T07:27:21","slug":"notizia-fragmin","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/notizia-fragmin","title":{"rendered":"Notizia"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-6a08b7802c2a5\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-6a08b7802c2a5\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/notizia-fragmin\/#FDA_approves_Fragmin-_an_anticoagulant_for_children\" >FDA approves Fragmin-\nan anticoagulant for children &nbsp;<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/notizia-fragmin\/#Symbicort_reduces_the_rate_of_Asthma_attack\" >Symbicort reduces the\nrate of Asthma attack<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/notizia-fragmin\/#New_trial_to_screen_Group_B_Strep_infections\" >New trial to screen\nGroup B Strep infections<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/notizia-fragmin\/#Owlstone_Actelion_inks_a_deal_for_early_detection_of_PH\" >Owlstone, Actelion inks\na deal for early detection of PH<\/a><\/li><\/ul><\/nav><\/div>\n\n<h4 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"FDA_approves_Fragmin-_an_anticoagulant_for_children\"><\/span><strong>FDA approves Fragmin-\nan anticoagulant for children &nbsp;<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h4>\n\n\n\n<p>The FDA today approved <strong>Fragmin <\/strong>for the treatment of blood clots. <strong>Pfizer\u2019s <\/strong>candidate Fragmin which was earlier approved for the treatment of only adults suffering from a fatal disease called <strong>VTE<\/strong>, which can include<a href=\"https:\/\/www.delveinsight.com\/report-store\/deep-vein-thrombosis-dvt-pipeline-insight\"> deep vein thrombosis<\/a> (<a href=\"https:\/\/www.delveinsight.com\/report-store\/blood-coagulation-factor-activators-pipeline-insight\">blood clot<\/a> in the deep veins of the leg) and <a href=\"https:\/\/www.delveinsight.com\/report-store\/pulmonary-embolism-market\">pulmonary embolism<\/a> (blood clot in the lungs), has now been approved to be used for children. This approval will benefit many children who are fighting cancer and struggling with serious conditions like VTE. <\/p>\n\n\n\n<h4 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Symbicort_reduces_the_rate_of_Asthma_attack\"><\/span><strong>Symbicort reduces the\nrate of Asthma attack<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h4>\n\n\n\n<p>The trials conducted by <strong>AstraZeneca<\/strong> for its novel <strong>Symbicort Turbuhaler<\/strong> (budesonide\/formoterol) demonstrated that the drug holds the potential to minimize or lower the rate of <strong>Asthma<\/strong> attacks. The trials published in the journal \u201cNew England Journal of Medicine\u201d stated that a reduction of around 51% was seen in the annual asthma severity. The successful trials of Symbicort will help decelerate the toll of asthma attacks which every year is around 176 million globally. <\/p>\n\n\n\n<h4 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"New_trial_to_screen_Group_B_Strep_infections\"><\/span><strong>New trial to screen\nGroup B Strep infections<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h4>\n\n\n\n<p>The <strong>National Institute for Health Research<\/strong> (NIHR) has announced to fund a new clinical trial to improve the diagnosis of any life-threatening diseases in newborn babies. The trials aim to detect any kind of disorders or bugs in pregnant women. The most commonly found <strong>Group B <\/strong><em><strong>Streptococcus<\/strong><\/em><strong> <\/strong>infections in women which can be passed down to babies and can pose harm. If screened properly, it can be prevented from passing it down by the administration of antibiotics during labor.  <\/p>\n\n\n\n<h4 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Owlstone_Actelion_inks_a_deal_for_early_detection_of_PH\"><\/span><strong>Owlstone, Actelion inks\na deal for early detection of PH<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h4>\n\n\n\n<p><strong>Owlstone Medical<\/strong> recently has joined hands with <strong>Actelion Pharmaceuticals<\/strong> to facilitate the early diagnosis of <strong>Pulmonary Hypertension<\/strong> and its subtypes. The program aims to build a breath-based test to detect PH early. The collaborative development program will involve the collection of breath exhaled volatile organic compounds from more than 1000 patients. Actelion will be the sole funding partner whereas, Owlstone will analyze the collected samples associated with <strong>Pulmonary Hypertension. <\/strong><\/p>\n","protected":false},"excerpt":{"rendered":"<p>FDA approves Fragmin- an anticoagulant for children &nbsp; The FDA today approved Fragmin for the treatment of blood clots. Pfizer\u2019s candidate Fragmin which was earlier approved for the treatment of only adults suffering from a fatal disease called VTE, which can include deep vein thrombosis (blood clot in the deep veins of the leg) and [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":5080,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[1875,96,704,4154,460,499,4063],"industry":[17225],"therapeutic_areas":[17243],"class_list":["post-5079","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-asthma","tag-astrazeneca","tag-fda","tag-fragmin","tag-pfizer","tag-pulmonary-arterial-hypertension","tag-pulmonary-arterial-hypertension-market-research","industry-pharmaceutical","therapeutic_areas-respiratory-diseases"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Notizia 21\/05\/2019 - DelveInsight Business Research<\/title>\n<meta name=\"description\" content=\"Fragmin approved for the treatment of adults.. a fatal disease called VTE...deep vein thrombosis and pulmonary embolism...\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/notizia-fragmin\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Notizia 21\/05\/2019 - DelveInsight Business Research\" \/>\n<meta property=\"og:description\" content=\"Fragmin approved for the treatment of adults.. a fatal disease called VTE...deep vein thrombosis and pulmonary embolism...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/notizia-fragmin\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2019-05-21T07:33:15+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-07-24T07:27:21+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/05\/09022909\/Notizia-new.png\" \/>\n\t<meta property=\"og:image:width\" content=\"647\" \/>\n\t<meta property=\"og:image:height\" content=\"345\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Notizia 21\/05\/2019 - DelveInsight Business Research","description":"Fragmin approved for the treatment of adults.. a fatal disease called VTE...deep vein thrombosis and pulmonary embolism...","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/notizia-fragmin","og_locale":"en_US","og_type":"article","og_title":"Notizia 21\/05\/2019 - DelveInsight Business Research","og_description":"Fragmin approved for the treatment of adults.. a fatal disease called VTE...deep vein thrombosis and pulmonary embolism...","og_url":"https:\/\/www.delveinsight.com\/blog\/notizia-fragmin","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2019-05-21T07:33:15+00:00","article_modified_time":"2021-07-24T07:27:21+00:00","og_image":[{"width":647,"height":345,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/05\/09022909\/Notizia-new.png","type":"image\/png"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/notizia-fragmin","url":"https:\/\/www.delveinsight.com\/blog\/notizia-fragmin","name":"Notizia 21\/05\/2019 - DelveInsight Business Research","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/notizia-fragmin#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/notizia-fragmin#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/05\/09022909\/Notizia-new.png","datePublished":"2019-05-21T07:33:15+00:00","dateModified":"2021-07-24T07:27:21+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"Fragmin approved for the treatment of adults.. a fatal disease called VTE...deep vein thrombosis and pulmonary embolism...","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/notizia-fragmin"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/notizia-fragmin#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/05\/09022909\/Notizia-new.png","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/05\/09022909\/Notizia-new.png","width":647,"height":345,"caption":"Recent Pharma News"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/05\/09022909\/Notizia-new-300x160.png","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">asthma<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">AstraZeneca<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">FDA<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Fragmin<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Pfizer<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Pulmonary arterial hypertension<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Pulmonary Arterial Hypertension market research<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">asthma<\/span>","<span class=\"advgb-post-tax-term\">AstraZeneca<\/span>","<span class=\"advgb-post-tax-term\">FDA<\/span>","<span class=\"advgb-post-tax-term\">Fragmin<\/span>","<span class=\"advgb-post-tax-term\">Pfizer<\/span>","<span class=\"advgb-post-tax-term\">Pulmonary arterial hypertension<\/span>","<span class=\"advgb-post-tax-term\">Pulmonary Arterial Hypertension market research<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 7 years ago","modified":"Updated 5 years ago"},"absolute_dates":{"created":"Posted on May 21, 2019","modified":"Updated on Jul 24, 2021"},"absolute_dates_time":{"created":"Posted on May 21, 2019 1:03 pm","modified":"Updated on Jul 24, 2021 12:57 pm"},"featured_img_caption":"Recent Pharma News","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/5079","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=5079"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/5079\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/5080"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=5079"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=5079"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=5079"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=5079"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=5079"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}